1. Evinacumab significantly lowered low-density lipoprotein (LDL) cholesterol levels in patients with homozygous familial hypercholesterolemia.
2. Patients receiving evinacumab did not demonstrate additional serious adverse events compared to the control group.
Evidence Rating Level: 1 (Excellent)
Study Rundown: Homozygous familial hypercholesterolemia occurs due to a loss-of-function variant in the low-density lipoprotein (LDL)...